# Bio-Techne (TECH) Forecast Calculator

Interactive five-year financial forecast and DCF for Bio-Techne. Adjust revenue growth, margins, capex, and WACC to update revenue, free cash flow, and enterprise value.

- Canonical: https://finamodel.com/companies/bio-techne/forecast
- Industry: Healthcare
- Forecast start year: 2026

## Historical data

| Year | Revenue | Free cash flow | EBITDA | Net income |
|---:|---:|---:|---:|---:|
| 2021 | 714006000 | 156208000 | 224890000 | 96072000 |
| 2022 | 738691000 | 153473000 | 240156000 | 229296000 |
| 2023 | 931032000 | 307863000 | 325043000 | 140410000 |
| 2024 | 1105599000 | 280364000 | 397659000 | 272051000 |
| 2025 | 1136702000 | 216149000 | 406182000 | 285263000 |

## Frequently asked questions

### What does Bio-Techne (TECH) do?

Bio-Techne Corporation is a global life sciences company that develops, manufactures, and sells bioactive reagents, analytical instruments, and precision diagnostics. It provides critical tools that assist scientific investigations into biological processes, drug discovery, and clinical diagnoses across its Protein Sciences and Diagnostics and Spatial Biology segments.

### How does Bio-Techne generate revenue?

Bio-Techne employs a "razor and razorblade" strategy, where proprietary instrument placements drive high-margin, long-term consumable pull-through. Its revenue is primarily generated from its Protein Sciences segment, which accounts for approximately 71.5% of FY2025 revenue, and its Diagnostics and Spatial Biology segment, contributing about 28.5%.

### What is the assumed revenue growth rate for Bio-Techne in this financial model?

The financial model for Bio-Techne assumes a revenue growth rate of approximately 12.33%. This key assumption is used to forecast the company's future financial performance from FY2026 to FY2030.

### What is the purpose of the Bio-Techne financial model?

The Bio-Techne financial model provides a comprehensive equity valuation and cash flow forecast for the company. It allows analysts to assess the impact of recent portfolio pruning, such as the Exosome Diagnostics divestiture, and the margin expansion trajectory of its core consumables-driven life sciences business.

### Can I download an Excel financial model for Bio-Techne (TECH)?

Yes, a downloadable Excel financial model is available for Bio-Techne (TECH). This model offers a forecast horizon from FY2026 to FY2030 and includes detailed assumptions for revenue growth, margins, and capital expenditures.

### What is Bio-Techne's strategy regarding acquisitions and divestitures?

Historically, Bio-Techne was a serial bolt-on acquirer, but it has recently shifted its strategic focus to portfolio pruning. This includes divesting non-core assets like its Fetal Bovine Serum business and Exosome Diagnostics CLIA-lab service in early FY2026 to improve overall segment profitability.